Andres Prieto Trujillo

Mr. Andres Prieto Trujillo

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2024 in Evolution
Verified
Journal Article
Closed access
PDF file
AHAndrew L Hardy
Andrew L Hardy
MGMichael R. Gaither
Michael R. Gaither
KLKatie E Lotterhos
Katie E Lotterhos
SGSamuel Greaves
Samuel Greaves
KCKyra Jean Cipolla
Kyra Jean Cipolla
MGMatthew R Gilg
Matthew R Gilg
Hybridization offers insight into speciation and the forces that maintain barriers to reproduction, and hybrid zones provide excellent opportunities to test how environment shapes barriers to reproduction and hybrid fitness. A hybrid zone between the killifish, Fundulus heteroclitus and F. grandis, had been identified in northeastern Florida, although the spatial structure and parameters that affect the distribution of the two species remain unknown. The present study aimed to determine the fine-scale spatial genetic patterns of the hybrid zone to test the hypothesis that species ranges are influenced by changes in dominant vegetation, and to determine how differences in reproductive barriers between the two species influence the observed patterns. The area of overlap between the two species spanned ~37 km and showed a mosaic pattern of hybridization, suggesting the spatial structure of the hybrid zone is largely influenced by the environment. Environmental association analysis, however, suggested that while dominant vegetation had a significant influence on the spatial structure of the hybrid zone, a combination of environmental factors was driving the observed patterns. Hybridization tended to be rare at sites where F. heteroclitus was the more abundant species, suggesting that differences in preference for conspecifics can lead to differences in rates of introgression into parental taxa and likely result in a range-shift as opposed to adaptation in the face of climate change.

28 November 2023
Verified
Book Chapter
Closed access
PDF file
Yash GuptaYash Gupta
Yash Gupta
SGSteven Goicoechea
Steven Goicoechea
JVJesse Vance
Jesse Vance
ATAndres Prieto Trujillo
Andres Prieto Trujillo
AAAkankcha Alok
Akankcha Alok
Prakasha KempaiahPrakasha Kempaiah
Prakasha Kempaiah

26 June 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
ATAndres Prieto Trujillo
Andres Prieto Trujillo
AUAnushri Umesh
Anushri Umesh
AHAbigail Hall
Abigail Hall
NANathan J. J Alves
Nathan J. J Alves
Fibrinolysis assessment is critical for diagnosing and managing clinical blood disorders. Currently available viscoelastic testing platforms provide an overview of global coagulation and fibrinolysis profiles but lack fibrinolysis specific assessment of a preformed clot substrate. The lack of a sensitive, standardized testing platform for fibrinolysis assessment can limit risk stratification and the management of blood disorders. We describe herein the plasma annular clot lysis assay. The assay adapts the previously standardized FITC-tagged fibrin annular clot assay to plasma obtained from healthy human donors. Plasmin at concentrations ranging from 200–800 nM was used as a direct thrombolytic to assess fibrinolysis in plasma-derived annular clots. The Maximum Fibrinolysis Rate (VMFR), FLU200, T90, and MaxFLU were calculated via tracking of the clot digestion curve over time. VMFR was correlated with plasma thromboelastography (TEG) parameters to compare with the global viscoelastic testing system. Additionally, plasma annular clot digestion was monitored in the presence of pentamidine to assess drug-specific effects on fibrinolysis tracking. Plasma annular clots linearly tracked fibrinolysis with increasing plasmin concentration. VMFR across multiple tested plasmin concentrations showed a moderate to strong negative correlation (0.58–0.74) with the observed maximum amplitude from plasma TEG. In the presence of pentamidine (75 µM), the assay was sensitive to identifying differences in the VMFR across treatment groups. Plasma annular clots provide a platform for fibrinolysis evaluation using a patient’s own plasma to assess therapeutic dosing clinically in addition to testing novel therapeutics preclinically to further understand mechanistic aspects of fibrinolysis.